As a dual GIP/GLP-1 receptor agonist, tirzepatide works through two pathways rather than one, which clinical trials have shown produces greater average weight loss compared to semaglutide alone
The weight loss in the SELECT trial wasnt especially large on average, each participant lost around 8 to 9 percent of their body weight
If injections become uncomfortable or difficult, speak with your healthcare provider rather than stopping treatment on your own
Semaglutide and Thyroid Cancer Concerns Mechanistic Theories of C-Cell Activation Animal data suggest GLP-1 receptor activation may stimulate rodent C-cell proliferation, but human thyroid C-cells express minimal GLP-1 receptors
Cagrilintide mimics a hormone called amylin, which tells your brain you are full
Du K, Williams CD, McGill MR, Jaeschke H